Aclarion, Inc. Announces Results of 2024 Annual Meeting of Stockholders

Aclarion, Inc. (NASDAQ: ACON) recently disclosed the outcomes of its 2024 Annual Meeting of Stockholders in a Form 8-K filing with the Securities and Exchange Commission. The meeting, which took place on December 31, 2024, covered several key proposals and election matters.

The first proposal involved the election of seven directors to serve until the 2024 annual meeting, or until their respective successors are elected and qualified. The nominees, including Jeffrey Thramann, Brent Ness, and others, received significant support from stockholders with all seven director nominees being duly elected.

The second proposal concerning the ratification of the independent registered accounting firm, Haynie & Company, was also successfully approved, with a substantial majority of votes in favor.

The third and fourth proposals, which involved the approval of share issuances pursuant to the Company’s equity line and Series B convertible preferred stock, were both approved, indicating stockholders’ alignment with the company’s strategic decisions.

Similarly, Proposal 5, related to the issuance of shares pursuant to the Company’s Series C convertible preferred stock and related warrants, also received approval from the stockholders.

Moreover, Proposal 6, which sought approval for a proposed reverse stock split, was endorsed by the majority of voting stockholders.

Lastly, Proposal 7 focused on an amendment to the 2022 equity incentive plan, and it received approval from the stockholders.

Aclarion, Inc. continues to demonstrate strong shareholder support for its corporate governance decisions and strategic direction, as evidenced by the positive outcomes of the Annual Meeting. John Lorbiecki, the Chief Financial Officer of Aclarion, Inc., signed the report on behalf of the company as outlined in the filing.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Aclarion’s 8K filing here.

Aclarion Company Profile

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.